Siklos® (hydroxyurea; Medunik) is now available in a 100mg scored tablet in addition to the 1000mg triple-scored tablets. Previously, the 100mg strength tablet was not scored.

Siklos is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients aged 2 years and older with sickle cell anemia with recurrent moderate to severe painful crises. 

The scored tablets help further optimize dosing in patients with sickle cell anemia. The 100mg tablets have 1 score line and can be split into 2 parts (each 50mg), while the 1000mg tablets have 3 score lines and can be split into 4 parts (each 250mg). For patients who are unable to swallow the tablets, Siklos can be dispersed immediately before use in a small quantity of water in a teaspoon. As Siklos is a cytotoxic drug, caregivers are advised to wear disposable gloves when handling tablets or bottles containing the drug.

Related Articles

“With the newly available Siklos 100mg scored tablets, dose adjustments can now be made in 50mg increments,” said Tanya Carro, General Manager, at Medunik USA. “Coupled with Siklos 1000mg triple-scored tablets (4 x 250mg), this will offer more accurate dose adjustments and may make it more convenient than compounded hydroxyurea.”


Continue Reading

For more information visit siklosusa.com.

References

  1. Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in 100 mg scored tablets to help further optimize dosing. [press release]. Rosemont, PA: Medunik USA; October 19, 2020. 
  2. Siklos [package insert]. Rosemont, PA: Medunik USA; 2020.